Skip to content
Forxiga
Active ingredient: Dapagliflozin

Forxiga

Quality products
24/7 Support
Fast delivery
Delivery from 4 days
Select pack Package Per unit Price

Free delivery on orders from AED 796.00, free express delivery from AED 1,194.00

Secure Payments
Track your order
Best price guarantee

Adults with type 2 diabetes, chronic heart failure, or chronic kidney disease may be prescribed Forxiga as part of an individualized treatment plan. Forxiga contains dapagliflozin, an SGLT2 inhibitor that helps the kidneys remove glucose and sodium through urine. It is taken by mouth as a tablet, usually once daily.

About this product

Forxiga contains dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. The medicine is used in adults with type 2 diabetes mellitus and is also prescribed for selected patients with heart failure or chronic kidney disease. Its benefits extend beyond blood glucose control because SGLT2 inhibition changes how the kidneys handle glucose, sodium, and fluid [1].

Pharmacological classification of dapagliflozin

SGLT2 proteins are located mainly in the proximal tubules of the kidneys. They normally help return filtered glucose and sodium to the bloodstream. Dapagliflozin reduces this reabsorption, allowing more glucose and sodium to leave the body in urine.

This process is called glucosuria. It lowers the amount of glucose retained in the bloodstream and produces a mild diuretic effect. The resulting reduction in fluid volume and pressure within the kidney can support cardiovascular and renal outcomes in appropriate patients.

Forxiga does not replace insulin. It also does not stimulate the pancreas to release insulin directly, so its action differs from medicines that increase insulin secretion.

Increased urination can occur after starting treatment. Taking the tablet earlier in the day may reduce disruption at night, especially when evening fluid intake is also limited.

Pharmacological action

Dapagliflozin acts at the kidney rather than directly on the pancreas. Glucose filtered from the blood passes through the renal tubules. SGLT2 inhibition allows some of that glucose to remain in the urine and leave the body during urination.

The medicine also increases sodium delivery to parts of the kidney involved in pressure regulation. This may reduce intraglomerular pressure, which is the pressure inside the kidney’s filtering units. Lower pressure can help reduce stress on the glomeruli in people with chronic kidney disease.

For heart failure, the clinical benefit is linked to several effects, including reduced sodium retention, modest fluid removal, and changes in cardiac and renal workload. These effects can occur even when a person does not have diabetes. The European Medicines Agency describes dapagliflozin as an SGLT2 inhibitor with indications extending across diabetes, heart failure, and chronic kidney disease [2].

The response is not identical in every patient. Kidney function, hydration, blood pressure, age, and other medicines influence both tolerability and the clinical result.

What it contains

Forxiga contains dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

Directions for use

The dose of Forxiga is decided individually, taking age, other medicines, kidney function, hydration status, and health conditions into account. The tablet is taken orally once daily, with or without food, at approximately the same time each day.

  • Swallow the tablet with water.
  • Take it at the prescribed strength and frequency.
  • Do not take extra tablets to compensate for a missed dose.
  • Continue fluid intake according to the plan agreed for diabetes, heart failure, or kidney disease.
  • Tell the prescriber about vomiting, diarrhoea, fever, fasting, or a planned operation.

A missed dose should be taken when remembered if the next scheduled dose is not close. If the next dose is due soon, skip the missed tablet and return to the regular schedule. Taking two doses together can increase the chance of dehydration and unwanted effects.

Forxiga may be paused temporarily during significant illness, prolonged fasting, severe vomiting, or before certain procedures. The timing depends on the illness and procedure, so the plan should be agreed in advance with the prescribing clinician. The FDA prescribing information highlights the need to assess volume status, kidney function, ketoacidosis risk, and factors that may increase dehydration [3].

A common practical problem is taking Forxiga while eating and drinking very little because of illness. Contact the prescriber promptly if you cannot keep fluids down or develop marked weakness, abdominal pain, or rapid breathing.

Reasons not to use it

  • Previous serious allergy to dapagliflozin or an excipient.
  • Current diabetic ketoacidosis or a history of recurrent ketoacidosis.
  • Type 1 diabetes unless managed within a specialist-approved setting.
  • Severe dehydration, persistent vomiting, or significant fluid loss.
  • Acute serious illness or a planned operation requiring prolonged fasting.
  • Advanced kidney impairment where the intended indication or dose is unsuitable.
  • Pregnancy, when alternative glucose treatment is generally preferred.
  • Breastfeeding, because treatment decisions must account for possible infant exposure and maternal glucose needs.
  • Low blood pressure or treatment with medicines that strongly increase urine output.
  • Recurrent genital or urinary infections requiring clinical evaluation.

Medicines that can increase dehydration risk include loop diuretics and other diuretic treatments. Insulin and insulin secretagogues may increase hypoglycaemia risk when used with Forxiga. Lithium requires special attention because changes in kidney handling and fluid balance can alter lithium concentrations.

When this is not for you

Forxiga is not suitable for every patient. Forxiga may not be for you if your diagnosis, kidney function, hydration status, or treatment risks do not fit an approved use.

The treatment plan should include current medicines, kidney disease, episodes of ketoacidosis, recurrent infections, alcohol intake, fasting patterns, and upcoming surgery. These details affect whether dapagliflozin is suitable and whether temporary interruption is needed.

Before an operation or a prolonged fast, mention Forxiga specifically rather than describing it only as a diabetes tablet. The perioperative plan for an SGLT2 inhibitor is different from the plan for several other glucose-lowering medicines.

Adverse reactions

The most common practical effects are increased urination, thirst, genital fungal infection, urinary tract infection, and dehydration-related symptoms. The chance of hypoglycaemia is usually low when Forxiga is used alone, but the risk rises when it is combined with insulin or medicines that increase insulin release.

Possible symptoms include:

  • Dry mouth or unusual thirst.
  • Dizziness when standing.
  • Increased urinary frequency.
  • Burning urination or pelvic discomfort.
  • Genital itching, redness, or discharge.
  • Fatigue related to fluid loss.
  • Constipation or nausea in some patients.

Genital infections are linked to the higher glucose concentration in urine. They can occur in both men and women. Early treatment is easier when symptoms are reported promptly.

Rare but serious reactions require urgent assessment. These include diabetic ketoacidosis, severe dehydration, acute kidney injury, serious urinary infection, necrotising infection of the perineum, and severe allergic reaction. Warning symptoms of ketoacidosis include nausea, vomiting, abdominal pain, unusual tiredness, confusion, or rapid breathing. Blood glucose can be lower than expected during ketoacidosis, so the absence of very high glucose does not rule it out.

Do not dismiss nausea and abdominal pain as a simple stomach upset when they occur with weakness or fast breathing. SGLT2 inhibitor-associated ketoacidosis can develop with only a modest glucose increase.

Patients sometimes notice more urination during the first days. This may settle as the body adjusts, but persistent dizziness, fainting, or inability to maintain fluid intake needs prompt medical review.

Uses

Forxiga may form part of treatment for:

  • Type 2 diabetes mellitus, alongside diet, physical activity, or other glucose-lowering medicines.
  • Chronic heart failure in adults meeting the clinical criteria for treatment.
  • Chronic kidney disease in adults who meet the approved indication and kidney-function requirements.
  • Reduction of diabetes-related renal and cardiovascular risk in selected patients.

Forxiga is not used to treat type 1 diabetes routinely. SGLT2 inhibitors can increase the risk of diabetic ketoacidosis in people with type 1 diabetes, including when blood glucose is not extremely high. The prescribing clinician must determine whether the patient’s diagnosis and kidney function fit the approved use.

Blood glucose may improve without symptoms changing immediately. Kidney and heart failure benefits are assessed through clinical follow-up, blood tests, blood pressure, weight, swelling, breathlessness, and kidney-function measurements.

Comparison

Treatment approach Main mechanism Practical distinction
Dapagliflozin, an SGLT2 inhibitor Increases urinary glucose and sodium excretion May support glucose control, heart failure care, and kidney protection in suitable adults
Metformin, a biguanide Reduces hepatic glucose production and improves insulin sensitivity Primarily targets glucose metabolism; gastrointestinal symptoms can limit use
Insulin therapy Replaces or supplements insulin Essential in type 1 diabetes and used when endogenous insulin is insufficient

Dapagliflozin can be used alongside other diabetes treatments when clinically appropriate. Combining glucose-lowering medicines may improve control, yet it can also alter the risk of hypoglycaemia, especially when insulin or insulin secretagogues are included.

Forxiga’s kidney and heart failure indications distinguish it from treatments that mainly target blood glucose. The choice depends on diagnosis, estimated glomerular filtration rate, blood pressure, fluid status, cardiovascular history, and the patient’s current regimen.

Common mistakes

Several mistakes can reduce benefit or increase risk:

  • Taking an additional tablet after a missed dose.
  • Continuing treatment through repeated vomiting or severe diarrhoea without seeking a sick-day plan.
  • Restricting fluids excessively because of concern about urinary frequency.
  • Ignoring genital itching, burning urination, or unusual discharge.
  • Assuming a normal or mildly raised glucose level excludes ketoacidosis.
  • Forgetting to mention Forxiga before surgery or prolonged fasting.
  • Using leftover prescription medicines after a new diagnosis or change in kidney function.
  • Stopping insulin without a specific medical plan.
  • Treating dizziness as unrelated when a diuretic is also being used.

One detail patients often miss is that urine glucose can remain increased while taking an SGLT2 inhibitor. A urine glucose result may therefore look abnormal even when the medicine is working as intended.

Another practical issue concerns blood pressure. Forxiga may contribute to lower blood pressure through fluid loss, which can be helpful for some patients but uncomfortable for someone already prone to postural dizziness.

What doctors say

In clinical practice, prescribers often assess three issues before starting dapagliflozin: the treatment goal, kidney function, and the patient’s ability to maintain hydration. A person taking Forxiga for heart failure may not notice a dramatic daily change, even when the medicine is contributing to fewer fluid-related problems over time.

Doctors also watch for a mismatch between the medicine and the patient’s routine. Frequent fasting, heavy exertion in hot weather, recurrent vomiting, or poorly controlled fluid restriction can increase the risk of dehydration or ketoacidosis.

The glucose result is only one part of follow-up. Clinicians may review estimated glomerular filtration rate, urinary albumin, blood pressure, weight, swelling, breathlessness, and genital or urinary symptoms. The American Diabetes Association continues to place SGLT2 inhibitors within a broader risk-based approach to diabetes and cardiorenal disease [4].

Patients switching from another glucose-lowering plan may expect an immediate subjective improvement. That expectation can be misleading. Dapagliflozin’s value may be reflected in laboratory trends and fewer heart failure or kidney complications rather than a noticeable sensation after each tablet.

Questions and answers

What should I do after missing a Forxiga dose?

Take the missed tablet when remembered unless the next scheduled dose is close. In that situation, skip the missed tablet and take the next dose at the usual time. Do not double the dose. FDA prescribing information current before 2026 supports avoiding extra dosing and highlights assessment of dehydration and ketoacidosis risk when treatment is interrupted or illness occurs .

Can Forxiga affect driving, concentration, or machinery work?

Forxiga itself does not usually impair alertness or coordination. Dizziness may occur when fluid loss lowers blood pressure, and hypoglycaemia becomes more likely when Forxiga is combined with insulin or an insulin secretagogue. Check how the treatment affects you before driving or operating machinery, especially after starting or changing the regimen. WHO diabetes guidance published in 2023 supports individual attention to hypoglycaemia and treatment-related risks during daily activities [5].

Is Forxiga suitable for older adults?

Older adults may use Forxiga when the indication, kidney function, blood pressure, and hydration status are suitable. Age-related reduction in kidney function and concurrent diuretic treatment can increase the chance of dizziness, dehydration, or acute kidney problems. Prescribers may monitor renal function and blood pressure more closely after treatment changes. EMA safety information from 2024 stresses assessment of volume status and renal function in patients at higher risk.

Can I drink alcohol while taking Forxiga?

Alcohol can worsen dehydration and may contribute to poor food intake, vomiting, or low blood glucose when other diabetes medicines are used. Heavy drinking or alcohol combined with fasting can also increase conditions associated with ketoacidosis. The safest approach is to discuss the usual amount and pattern of alcohol use before treatment begins. FDA prescribing information available before 2026 identifies reduced food intake, illness, and volume depletion as factors that can raise ketoacidosis risk.

What should I discuss with a doctor before starting Forxiga?

Discuss the reason for treatment, kidney disease, previous ketoacidosis, recurrent genital or urinary infections, low blood pressure, diuretic use, insulin treatment, pregnancy plans, breastfeeding, and upcoming surgery. Mention periods of fasting, heavy exercise in hot weather, vomiting, or diarrhoea because these can change the sick-day plan. A medication review should include non-prescription products and recent changes in fluid or salt advice. NICE guidance updated before 2026 recommends treatment choices based on glycaemic, renal, cardiovascular, and individual safety factors.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Compare treatments for Diabetes

Sources

  1. European Medicines Agency (2024). Forxiga: European public assessment report and product information for dapagliflozin
  2. European Medicines Agency (2024). Forxiga: Summary of Product Characteristics
  3. U.S. Food and Drug Administration (2023). Farxiga (dapagliflozin) prescribing information
  4. American Diabetes Association (2025). Standards of Care in Diabetes—2025
  5. World Health Organization (2023). Diagnosis and management of type 2 diabetes

Forxiga: What Customers Say

3.9
Based on 4 reviews
Waleed, 49 Madinat Zayed Several months
Verified
Rating: 4.5 out of 5

My glucose readings became easier to manage after the first few weeks. I urinated more often at the beginning, so taking it in the morning worked better for my workday. I had to pay more attention to drinking enough water.

5 Oct 2026
Bilal Z., 51 Al Barsha About two months
Verified
Rating: 3.5 out of 5

The medicine fitted into my routine without stomach problems. I did notice thirst on hot days and felt light-headed once after spending hours outdoors. My clinician adjusted the wider treatment plan, and that problem did not continue.

13 Oct 2026
James, 39 Mussafah Several weeks
Verified
Rating: 4 out of 5

I stopped it during a bout of vomiting after receiving specific sick-day instructions. The first weeks had more urination than I expected, and I was not impressed at first. Once my routine settled, taking it became straightforward.

19 Oct 2026
Nadeem, 66 Jebel Ali Many months
Verified
Rating: 3.5 out of 5

The main benefit for me was part of a wider heart failure plan rather than a feeling I could notice from one tablet. I had one episode of genital irritation that needed treatment. Since then, I report symptoms early instead of waiting.

31 Oct 2026
Get our free app Shop faster and track your orders 3.8 · 441 reviews Install